Stuart Turner

1.6k total citations · 1 hit paper
42 papers, 1.1k citations indexed

About

Stuart Turner is a scholar working on Cardiology and Cardiovascular Medicine, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Stuart Turner has authored 42 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Cardiology and Cardiovascular Medicine, 13 papers in Pulmonary and Respiratory Medicine and 7 papers in Oncology. Recurrent topics in Stuart Turner's work include Heart Failure Treatment and Management (15 papers), Advanced Breast Cancer Therapies (7 papers) and Health Systems, Economic Evaluations, Quality of Life (5 papers). Stuart Turner is often cited by papers focused on Heart Failure Treatment and Management (15 papers), Advanced Breast Cancer Therapies (7 papers) and Health Systems, Economic Evaluations, Quality of Life (5 papers). Stuart Turner collaborates with scholars based in United States, United Kingdom and Switzerland. Stuart Turner's co-authors include Gregg C. Fonarow, Katie J. Suda, James M. Hoffman, Fred Doloresco, Alexandra Pérez, Daniel R. Touchette, Yash J. Jalundhwala, Hemanth Kanakamedala, Wei‐Chun Hsu and Juan Pablo Zarate and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Journal of the American College of Cardiology.

In The Last Decade

Stuart Turner

40 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study

2021 223 citations Hope S. Rugo, Florence Lerebours et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Stuart Turner United States	16	366	332	190	174	121	42	1.1k
Jonas Lundkvist Sweden	20	298 0.8×	528 1.6×	181 1.0×	52 0.3×	211 1.7×	49	1.5k
Ágnes Benedict United States	18	105 0.3×	221 0.7×	283 1.5×	138 0.8×	418 3.5×	57	1.2k
James Chan United States	18	80 0.2×	87 0.3×	139 0.7×	185 1.1×	141 1.2×	29	947
Lucie Kutikova Switzerland	16	109 0.3×	129 0.4×	315 1.7×	44 0.3×	335 2.8×	53	1.0k
E. Alemao United States	23	168 0.5×	147 0.4×	52 0.3×	42 0.2×	373 3.1×	118	1.5k
Lee N. Newcomer United States	18	76 0.2×	149 0.4×	356 1.9×	167 1.0×	486 4.0×	59	1.4k
Virginie Nerich France	20	50 0.1×	194 0.6×	334 1.8×	110 0.6×	208 1.7×	83	1.2k
Ginah Nightingale United States	19	102 0.3×	198 0.6×	294 1.5×	776 4.5×	343 2.8×	48	1.2k
Claire Siemes Netherlands	13	136 0.4×	109 0.3×	250 1.3×	91 0.5×	28 0.2×	21	869
Joel Wallace United States	10	84 0.2×	105 0.3×	111 0.6×	111 0.6×	254 2.1×	18	803

Countries citing papers authored by Stuart Turner

Since Specialization

Citations

This map shows the geographic impact of Stuart Turner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stuart Turner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stuart Turner more than expected).

Fields of papers citing papers by Stuart Turner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stuart Turner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stuart Turner. The network helps show where Stuart Turner may publish in the future.

Co-authorship network of co-authors of Stuart Turner

This figure shows the co-authorship network connecting the top 25 collaborators of Stuart Turner. A scholar is included among the top collaborators of Stuart Turner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stuart Turner. Stuart Turner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Largent, Joan, et al.. (2024). Important tool in our rare disease toolbox: hybrid retrospective-prospective natural history studies serve well as external comparators for rare disease studies. SHILAP Revista de lepidopterología. 4. 1418050–1418050. 1 indexed citations

Rugo, Hope S., Florence Lerebours, Eva Ciruelos, et al.. (2021). Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study. The Lancet Oncology. 22(4). 489–498. 223 indexed citations breakdown →

Turner, Stuart, Stephen Chia, Hemanth Kanakamedala, et al.. (2021). Effectiveness of Alpelisib + Fulvestrant Compared with Real-World Standard Treatment Among Patients with HR+, HER2–, PIK3CA-Mutated Breast Cancer. The Oncologist. 26(7). e1133–e1142. 23 indexed citations

Twelves, Chris, Sue Cheeseman, Will Sopwith, et al.. (2020). Systemic treatment of hormone receptor positive, human epidermal growth factor 2 negative metastatic breast cancer: retrospective analysis from Leeds Cancer Centre. BMC Cancer. 20(1). 53–53. 11 indexed citations

Neoh, Chin Fen, Esin Şenol, Ateş Kara, et al.. (2018). Economic evaluation of micafungin versus liposomal amphotericin B (LAmB) for treating patients with candidaemia and invasive candidiasis (IC) in Turkey. European Journal of Clinical Microbiology & Infectious Diseases. 37(9). 1777–1784. 3 indexed citations

Greene, Stephen J., Emily C. O’Brien, Robert J. Mentz, et al.. (2018). Home-Time After Discharge Among Patients Hospitalized With Heart Failure. Journal of the American College of Cardiology. 71(23). 2643–2652. 70 indexed citations

Luo, Nancy, Gregg C. Fonarow, Steven Lippmann, et al.. (2017). Early Adoption of Sacubitril/Valsartan for Patients With Heart Failure With Reduced Ejection Fraction. JACC Heart Failure. 5(4). 305–309. 93 indexed citations

Deschaseaux, C., et al.. (2016). Treatment Initiation Patterns, Modifications, and Medication Adherence Among Newly Diagnosed Heart Failure Patients: A Retrospective Claims Database Analysis. Journal of Managed Care & Specialty Pharmacy. 22(5). 561–571. 37 indexed citations

Swindle, Jason, et al.. (2016). Healthcare Costs Among Patients with Heart Failure: A Comparison of Costs between Matched Decedent and Survivor Cohorts. Advances in Therapy. 34(1). 261–276. 9 indexed citations

10.

Swindle, Jason, et al.. (2016). Health Care Costs for Patients with Heart Failure Escalate Nearly 3-Fold in Final Months of Life. Journal of Managed Care & Specialty Pharmacy. 22(12). 1446–1456. 23 indexed citations

11.

Gaziano, Thomas A., Gregg C. Fonarow, Brian Claggett, et al.. (2016). Cost-effectiveness Analysis of Sacubitril/Valsartan vs Enalapril in Patients With Heart Failure and Reduced Ejection Fraction. JAMA Cardiology. 1(6). 666–666. 111 indexed citations

12.

Swindle, Jason, et al.. (2015). HEALTHCARE COSTS AND RESOURCE UTILIZATION IN HEART FAILURE: DIFFERENCES BASED ON HEART FAILURE HISTORY. Journal of the American College of Cardiology. 65(10). A1049–A1049. 1 indexed citations

13.

Vietri, Jeffrey, Stuart Turner, Haijun Tian, et al.. (2015). Effect of chronic urticaria on US patients: analysis of the National Health and Wellness Survey. Annals of Allergy Asthma & Immunology. 115(4). 306–311. 62 indexed citations

14.

Hasegawa, Kohei, Ashley F. Sullivan, Yusuke Tsugawa, et al.. (2014). Comparison of US emergency department acute asthma care quality: 1997-2001 and 2011-2012. Journal of Allergy and Clinical Immunology. 135(1). 73–80.e7. 1 indexed citations

15.

Li, Yunfeng, Haijun Tian, Michael J. Goodman, et al.. (2014). Costs and health care resource utilization among chronic obstructive pulmonary disease patients with newly acquired pneumonia. ClinicoEconomics and Outcomes Research. 6. 349–349. 13 indexed citations

16.

Hasegawa, Kohei, D. Matthew Sullivan, Theodore J. Gaeta, et al.. (2014). A Multicenter Observational Study of US Adults with Acute Asthma: Who Are the Frequent Users of the Emergency Department?. The Journal of Allergy and Clinical Immunology In Practice. 2(6). 733–740.e3. 30 indexed citations

17.

Turner, Stuart, Sharon C.‐A. Chen, Monica A. Slavin, & David C. M. Kong. (2013). Pharmacoeconomics of empirical antifungal use in febrile neutropenic hematological malignancy and hematopoietic stem cell transplant patients. Expert Review of Pharmacoeconomics & Outcomes Research. 13(2). 227–235. 7 indexed citations

18.

Turner, Stuart, Jack Brown, & Joseph A. Paladino. (2013). Protease Inhibitors for Hepatitis C: Economic Implications. PharmacoEconomics. 31(9). 739–751. 3 indexed citations

19.

Soon, Rachel L., Stuart Turner, Alan Forrest, Brian T. Tsuji, & Jack Brown. (2013). Pharmacokinetic/pharmacodynamic evaluation of the efficacy and safety of daptomycin against Staphylococcus aureus. International Journal of Antimicrobial Agents. 42(1). 53–58. 17 indexed citations

20.

Longhurst, Chris, Stuart Turner, & Anthony E. Burgos. (2009). Development of a Web-based Decision Support Tool to Increase Use of Neonatal Hyperbilirubinemia Guidelines. The Joint Commission Journal on Quality and Patient Safety. 35(5). 256–262. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact